Tragara’s TG02 is Highly Active in CLL Cells Derived from Patients
28 May 2014
TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy.
Marinus braves a cooling biotech IPO market with a $63M pitch
13 May 2014
A bit more than a year after Domain and its colleagues at RusNano put up a $21 million C round, New Haven, CT-based Marinus Pharmaceuticals is hoping to catch the wave of biotech IPOs. Marinus has filed an S-1 outlining plans to raise $63 million on Nasdaq, even as the latest round of new biotech offerings has seen several painful stumbles out of the gate.
LA BioMed woos deep pockets interested in its lifesaving research
06 May 2014
From iodine eyedrops that prevent blindness in children to cholesterol testing to early discoveries that led to in vitro fertilization, the Los Angeles Biomedical Research Institute has made innovative scientific breakthroughs with worldwide implications since 1962.
Advances in Presbyopia Correction
23 April 2014
Hello. I'm Dr. Roger Steinert, Chair of Ophthalmology and Director of the Gavin Herbert Eye Institute at the University of California, Irvine. I just returned from the World Ophthalmology Congress, held this year in Tokyo, Japan, and had the opportunity to participate in several sessions on presbyopia treatments with intracorneal inlays.
Syndax Plots $69M IPO For Cancer Drug’s Stretch Run
28 March 2014
Syndax Pharmaceuticals raised about $27 million in private financing last year to gear up for a late-stage clinical trial. Now, on the doorstep of that lengthy, 600-patient study, the Waltham, MA-based company is looking to Wall Street to get it to the finish line.
Syndax Files Registration Statement for Proposed Initial Public Offering
27 March 2014
Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined.
ECOG-ACRIN Opens Phase III Trial of Syndax’s Entinostat in Advanced Breast Cancer
20 March 2014
Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112.
Hydrogel corneal inlay improves near, intermediate, distance vision at 3 months
17 February 2014
A hydrogel corneal inlay improved near, intermediate and distance vision, regardless of preoperative refractive error, according to a study presented at Hawaiian Eye 2014.
Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director
03 February 2014
Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director. Dr. Sledge is currently professor and chief of medical oncology at Stanford University Medical Center.
Marinus Pharmaceuticals Bolsters Its Board of Directors and Executive Management
13 January 2014
Elects Two Life Sciences Veterans, Enrique J. Carrazana, M.D. and Jay P. Shepard, to Its Board of Directors; Appoints Edward F. Smith as Chief Financial Officer.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024